593 related articles for article (PubMed ID: 21308679)
1. [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ].
Ruoppolo M; Gozo M; Milesi R; Spina R; Fragapane G
Urologia; 2010; 77 Suppl 17():72-7. PubMed ID: 21308679
[TBL] [Abstract][Full Text] [Related]
2. [Prostatic involvement by urothelial carcinoma in patients with bladder cancer and their implications in the clinical practice].
Huguet J
Actas Urol Esp; 2012 Oct; 36(9):545-53. PubMed ID: 22520044
[TBL] [Abstract][Full Text] [Related]
3. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H
Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Taylor JH; Davis J; Schellhammer P
Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
[TBL] [Abstract][Full Text] [Related]
5. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
6. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
7. Urothelial carcinoma in the prostatic urethra and prostate: current controversies.
Liedberg F; Chebil G; Månsson W
Expert Rev Anticancer Ther; 2007 Mar; 7(3):383-90. PubMed ID: 17338657
[TBL] [Abstract][Full Text] [Related]
8. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
9. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
10. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Luciani LG; Neulander E; Murphy WM; Wajsman Z
Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
[TBL] [Abstract][Full Text] [Related]
11. [Transitional cell carcinoma of the prostate in cystoprostatectomy specimens].
Liedberg F; Chebil G; Davidsson T; Malmström PU; Sherif A; Månsson W
Aktuelle Urol; 2003 Sep; 34(5):333-6. PubMed ID: 14566661
[TBL] [Abstract][Full Text] [Related]
12. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate.
Palou J; Xavier B; Laguna P; Montlleó M; Vicente J
Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354
[TBL] [Abstract][Full Text] [Related]
13. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
14. [Membranous and penile urethral involvement in bladder cancer patients-- review of cystoprostatourethrectomy specimens].
Shimizu T; Suzuki T; Yamanaka H; Satoh J; Suzuki K
Hinyokika Kiyo; 1994 Oct; 40(10):869-72. PubMed ID: 7992699
[TBL] [Abstract][Full Text] [Related]
15. Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.
Pieras E; Palou J; Salvador J; Rosales A; Marcuello E; Villavicencio H
Eur Urol; 2003 Aug; 44(2):222-5; discussoion 225. PubMed ID: 12875942
[TBL] [Abstract][Full Text] [Related]
16. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.
Bretton PR; Herr HW; Whitmore WF; Badalament RA; Kimmel M; Provet J; Oettgen HF; Melamed MR; Fair WR
J Urol; 1989 Apr; 141(4):853-6. PubMed ID: 2926879
[TBL] [Abstract][Full Text] [Related]
17. [Radical cystectomy for superficial tumors in the BCG era].
Huguet Pérez J; Palou J; Millán Rodríguez F; Villavicencio Mavrich H; Rodríguez JV
Arch Esp Urol; 2002; 55(1):50-6. PubMed ID: 11957752
[TBL] [Abstract][Full Text] [Related]
18. Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution.
Varol C; Thalmann GN; Burkhard FC; Studer UE
J Urol; 2004 Sep; 172(3):937-42. PubMed ID: 15311003
[TBL] [Abstract][Full Text] [Related]
19. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin.
Hillyard RW; Ladaga L; Schellhammer PF
J Urol; 1988 Feb; 139(2):290-3. PubMed ID: 3339727
[TBL] [Abstract][Full Text] [Related]
20. [The recurrence of urothelial carcinoma in situ at the fossa navicularis of the urethra and the glans penis arising eight years after transurethral resection of a bladder tumor to treat superficial bladder cancer].
Nishizawa S; Inagaki T; Mori T; Kohjimoto Y; Suzuki A; Uekado Y; Shinka T
Hinyokika Kiyo; 2006 Mar; 52(3):223-6. PubMed ID: 16617879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
